Diabetes Mellitus and Hypertension as Risk Factors for Chronic Kidney Disease in Young Adults Attending Benghazi Nephrology Center: A Cross-Sectional Study (2019–2022)
DOI:
https://doi.org/10.54361/LJMR.20.1.06Keywords:
Chronic kidney diseases, young adults, hypertension, diabetes mellitus, hemodialysisAbstract
Background: Chronic kidney disease (CKD) is kidney damage or a low glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² for more than 3 months. Diabetes mellitus, hypertension, glomerulonephritis, and polycystic kidney disease are the main underlying causes of CKD.Aim: To assess diabetes mellitus and hypertension as risk factors for chronic kidney disease (CKD), in the AL-Hawari Nephrology Center, in Benghazi, Libya, in young adults aged between 18 and 40 years, through the period from 2019 to 2022.Materials and methods: This study was a retrospective cross-sectional design. The data were collected from the medical records of admitted patients and the outpatient clinic at Al Hawari Nephrology Center in Benghazi, Libya. Results: The total number of patients during the study period was 408. The mean age± SD was 30 ± 7 years, with male to female ratio of 1.3:1; the prevalence of CRF in the aged 18 to 40 years was 81.6 patients per 100,000 population. In our study, regarding the risk factors the hypertension was identified 195 patients (47.8%), diabetes mellitus was 77 patients (18.9%), single kidney patients in 53 patients (13%), polycystic kidney disease in 40 patients (10%), glomerulonephritis in 26 patients (6.4%), and autoimmune diseases among 19 patients (4.7%). The combined of both risk factors, hypertension and diabetes mellitus, is together (13.9%). Regarding CKD outcome, stage 4 and 5 CKD among 48 patients (11.8 %), hemodialysis patients in 41 patients (10%), and 123 patients (30%) were lost to follow-up. Conclusion: Hypertension and diabetes mellitus were the main causes of CKD. Near quarter of patients progressed to the advanced stage of CKD.
Downloads
References
1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11.
2. National Kidney Foundation. DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2).
3. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31(6):868–74.
4. Kalyesubula R, Makanga G, Gyagenda JO, Atuhe D, Kansiime G, Kiggundu D, et al. Nephrology in Uganda. In: Nephrology Worldwide. Cham: Springer International Publishing; 2021. p. 75–83.
5. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 2017;2(2).
6. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.
7. Van Der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. Kidney Int. 2011;79(12):1341–52.
8. Sun P, Ming X, Song T, Chen Y, Yang X, Sun Z, et al. Global burden of chronic kidney disease in adolescents and young adults, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2024;15:1389342.
9. Liu Y, He Q, Li Q, Tian M, Li X, Yao X, et al. Global incidence and death estimates of chronic kidney disease due to hypertension from 1990 to 2019. BMC Nephrol. 2023;24(1):352.
10. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.
11. Centers for Disease Control and Prevention. Chronic kidney disease (CKD) surveillance system. 2021. [Accessed 2021 Sep 30]. Available from: https://nccd.cdc.gov/ckd/default.aspx
12. Sugahara M, Pak WL, Tanaka T, Tang SC, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 2021;26(6):491–500.
13. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803–5.
14. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US renal data system 2019 annual data report. Am J Kidney Dis. 2020;75(1):A6–7.
15. Collaborators GB. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013. Lancet. 2015;385(9963):117–71.
16. Rhee CM, Kovesdy CP. Spotlight on CKD deaths—increasing mortality worldwide. Nat Rev Nephrol. 2015;11(4):199–200.
17. Almaguer M, Herrera R, Orantes CM. Chronic Kidney Disease of Unknown Etiology in Agricultural Communities. MEDICC Rev. 2014;16:9–15.
18. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements. 2022 Apr 1;12(1):7-11.
19. Habas EM, Elamouri J, Rayani AA. Chronic kidney disease in Libya, cross-sectional single center study.
20. Goleg FA, Kong NC, Sahathevan R. Dialysis-treated end-stage kidney disease in Libya: Epidemiology and risk factors. International urology and nephrology. 2014 Aug;46(8):1581-7.
21. Al-taworghei AH, Al-saqer ES, Erhoma EA, Sabei LT, Abukres SH. Chronic Kidney disease among a sample of Libyan population: What are †Žthe leading Risk Factors? †Ž. Lebda Medical Journal. 2019 Dec 20;6(1):221-4.
22. Banaga AS, Mohammed EB, Siddig RM, Salama DE, Elbashir SB, Khojali MO, Babiker RA, Elmusharaf K, Homeida MM. Causes of end stage renal failure among haemodialysis patients in Khartoum State/Sudan. BMC research notes. 2015 Sep 29;8(1):502.
23. Ghonemy TA, Farag SE, Soliman SA, El-Okely A, El-Hendy Y. Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt. Saudi Journal of Kidney Diseases and Transplantation. 2016 Jan 1;27(1):111-7.
24. Barsoum RS. Burden of chronic kidney disease: North Africa. Kidney Int Suppl. 2013;3(2):164-6.
25. Alahrash AA, Almjdoub OH, Elfarrah N, Aburas K, Abukhdir A, Abdull AM, Bahroen S. Cross sectional Study about Risk factors of increase the chronic kidney disease (CKD) in Wadi Ataba City southern Libya.
26. Alashek, W.A., McIntyre, C.W. & Taal, M.W. Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya. BMC Nephrol 13, 33 (2012).
27. Gusbi E, Abrahem AF, Elfituri A, Eltaib F, Benbubaker WM, Alhudiri IM, et al. Causes of end-stage renal disease among hemodialysis patients in Libya: A multicenter cross-sectional study. Libyan J Med Sci 2021; 5:139-43.
28. Tedla FM, Brar A, Browne R, Brown C. Hypertension in chronic kidney disease: navigating the evidence. International journal of hypertension. 2011;2011(1):132405.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Intesar.M. Herwees, Ghazala Othman Elfeitouri, Salah El-din Amer, Al-Saliheen Mohamed Majeed, Saad Mustafa Mostafa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
